The last draft guidance on using clinical outcomes assessments (COA) as endpoints in patient-focused drug development (PFDD) should use terminology more consistently, align more closely to other PFDD ...
Early in the new year, the US Food and Drug Administration (FDA) released two anticipated draft guidance documents focused on artificial intelligence (AI): Artificial Intelligence-Enabled Device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results